Charles Schwab Investment Management Inc. Grows Stock Holdings in AxoGen, Inc. (NASDAQ:AXGN)

Charles Schwab Investment Management Inc. boosted its holdings in shares of AxoGen, Inc. (NASDAQ:AXGN) by 8.6% during the third quarter, Holdings Channel.com reports. The firm owned 363,764 shares of the medical equipment provider’s stock after acquiring an additional 28,659 shares during the period. Charles Schwab Investment Management Inc.’s holdings in AxoGen were worth $5,100,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Intech Investment Management LLC purchased a new position in AxoGen in the 3rd quarter worth about $173,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in AxoGen by 66.3% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 308,686 shares of the medical equipment provider’s stock worth $4,328,000 after buying an additional 123,118 shares during the period. Quest Partners LLC increased its stake in AxoGen by 23,066.7% in the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 2,076 shares during the period. Oppenheimer & Co. Inc. purchased a new position in AxoGen in the 3rd quarter worth about $156,000. Finally, Los Angeles Capital Management LLC purchased a new position in AxoGen in the 3rd quarter worth about $279,000. Hedge funds and other institutional investors own 80.29% of the company’s stock.

AxoGen Stock Down 3.0 %

Shares of AxoGen stock opened at $14.41 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. AxoGen, Inc. has a 1 year low of $5.55 and a 1 year high of $15.90. The firm’s 50-day moving average is $13.81 and its two-hundred day moving average is $11.38. The stock has a market cap of $634.16 million, a price-to-earnings ratio of -45.03 and a beta of 1.06.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, AxoGen currently has an average rating of “Buy” and an average target price of $15.00.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.